注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Nuvalent Inc是一家临床前阶段的生物制药公司,专注于为癌症患者创造精确的靶向治疗。该公司正在推进一系列候选产品,连同由ROS原癌基因1(ROS1)和间变性淋巴瘤激酶(ALK)的基因组改变驱动的癌症平行计划,以及多个研发阶段的研究计划。其主要候选产品NVL-520是一种ROS1选择性抑制剂,旨在应对紧急治疗耐药、中枢神经系统(CNS)相关不良事件和脑转移的临床挑战。该公司的候选产品还包括NVL-655,它是一种脑穿透性ALK选择性抑制剂,旨在解决紧急治疗耐药、CNS相关不良事件和可能限制第一代、二代和三代ALK抑制剂使用的脑转移的临床挑战。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Matthew D. Shair | 54 | 2017 | Founder, Head of Scientific Advisory Board & Director |
James R. Porter | 47 | 2020 | CEO, President & Director |
Anna Protopapas | 58 | 2022 | Independent Chairman |
Sapna Srivastava | 52 | 2021 | Independent Non-Executive Director |
Emily Drabant Conley | 41 | 2022 | Independent Director |
Joseph Pearlberg | 58 | 2021 | Independent Non-Executive Director |
Alexander Drilon | - | 2021 | Member of Scientific Advisory Board |
Cameron A. Wheeler | 44 | 2017 | Independent Non-Executive Director |
Andrew A. F. Hack | 49 | 2021 | Independent Non-Executive Director |
Aaron Hata | - | - | Member of Scientific Advisory Board |
Nancy Kohl | - | - | Member of Scientific Advisory Board |
D. Ross Camidge | - | - | Member of Scientific Advisory Board |
D. Gary Gilliland | 68 | 2021 | Independent Non-Executive Director |
Michael L. Meyers | 72 | 2022 | Independent Director |
Pasi Antero Janne | - | - | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核